### The Irish Longitudinal Study on Ageing

https://neurodegenerationresearch.eu/survey/the-irish-longitudinal-study-on-ageing/

### Title of cohort

The Irish Longitudinal Study on Ageing

### Acronym for cohort

TILDA

### Name of Principal Investigator - Title

Prof

Name of Principal Investigator - First name

Rose Anne

### Name of Principal Investigator - Last name

Kenny

### **Address of institution -Institution**

Trinity College Dublin

### Address of institution - Street address

Lincoln Place

### Address of institution - City

Dublin

### Address of institution - Postcode

D2

### Country

Ireland

### Website

www.tilda.ie

**Contact email** 

#### rkenny@tcd.ie; hevera@tcd.ie

#### **Funding source**

Department of Health, Ireland & Atlantic Philanthropies

### Q1a. Please indicate below if your cohort includes or expects to include, incidence of the following conditions?

Neurodegenerative disease in general

#### Q1b. When are studies on the above condition(s) expected to become possible?

Already possible

#### Q2a. In a single sentence what is the stated aim of the cohort?

To collect high quality, longitudinal, multidisciplinary data to determine the health, social and economic status and needs of older people, and the biological and environmental components of successful ageing.

#### Q2b. What distinguishes this cohort from other population cohorts?

To collect high quality, longitudinal, multidisciplinary data to determine the health, social and economic status and needs of older people, and the biological and environmental components of successful ageing.

### Q3a. i) Number of publications that involve use of your cohort to date Q3a.ii) Please give up to three examples of studies to date (Principal Investigator, Institution, Title of Study)

Q3b. If data on research outputs are already available please paste the publication list/other data or provide a link to where these data are publicly available

http://tilda.tcd.ie/research/accessing-data/

Q3c. If no research has been done as yet, please explain in a few sentences what information (i.e. research findings) you expect will be gained from the population Q4a. Study criteria: what is the age range of participants at recruitment? Age in years From:

50

Q4a. Study criteria: what is the age range of participants at recruitment? To:

until death

#### Q4b. Study criteria: what are the inclusion criteria?

Age 50 and over (partner/spouse any age), community dwelling, cognitively intact

Q4c. Study criteria: what are the exclusion criteria?

Must be cognitively intact to complete interview

### Q5. What is the size of the cohort (i.e. how many participants have enrolled)?

5,001-10,000 participants

### **Q6a.** Please describe what measures are used to characterise participants

Interviews, self-completion questionnaires, health assessment

### Q6b. Are there additional measures for participants with a clinical disorder?

No

### Q6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)?

No

#### If yes please specify Q7. What is the study design (select all that apply)?

Longitudinal

### Q8. Are your cases matched by

Other health assessment

### Q9a. Does your study include a specialised subset of control participants?

No

## Q9b. If your study includes a specialised subset of control participants please describe Q10a. i) Please enter the data collection start date

01/01/2009

### Q10a. ii) Please enter the data collection end date

01/01/2021

### Q10a. iii) Is data collection for this study

Data collection ongoing|Data analysis ongoing

## Q10b. If data collection is ongoing, are there plans to continue the cohort study beyond the current projected end date?

Yes - funding applied for/funding awarded

### Q11. Is data collected

Only through the study

#### Other please specify here

Collected data is linked to other records such as mortality, medication use

### Q12. Is there a system in place to enable re-contact with patients to ask about participation in future studies?

No

### Q13a. Please give information on the format and availability of data stored in a database (1)

Data summarised in database

#### % available

100

Q13a. Please give information on the format and availability of data stored in a database (2)

No

% available

Q13a. Please give information on the format and availability of data stored in a database (3)

% available

Q13a. Please give information on the format and availability of data stored in a database (4)

% available

Other (please specify)

% available

Q13b. Please give information on the format and availability of data held as individual records (1)

% available

Q13b. Please give information on the format and availability of data held as individual records (2)

% available

Q13b. Please give information on the format and availability of data held as individual records (3)

Data held on computer based records

% available

# Q13b. Please give information on the format and availability of data held as individual records (4) % available Please specify language used

English

### Q14a. Is data available to other groups?

Yes

### Q14b. If data is available to other groups what is the access policy/mechanisms for access?

Apply to PI or co-ordinator at resource|Access through collaboration with PI only| Access independent of collaboration with PI|Access committee mechanism|Other access mechanism|Local/ regional access|National access|International access|Access to industry|Public dataset available

### Q15. What data sharing policy is specified as a condition of use?

Data made publicly available after a specified time point

### Q16a. Are tissues/samples/DNA available to other groups?

Yes

### Q16b i) If yes, please describe below:

Living donors: blood|Living donors: blood derivatives|Living donors: DNA

### Q16b. ii) In what form are tissues/samples/DNA supplied?

Primary samples: Supplied fresh

### Q16b. iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data (Q14 above)?

No

### Q17. Is information on biological characteristics available to other groups?

Yes, for all the cohort

Number of Patients % of total cohort

### Types:

100

### **Population Cohorts**

Member States: Ireland

Diseases:

Neurodegenerative disease in general

### Years:

2016

### Database Categories: N/A

Database Tags:

N/A